As the first meta-analysis to comprehensively and quantitatively evaluate the relationship between noninvasive biomarkers and NAFLD, this study demonstrates that CK-18, FGF-21, and related biomarker panel can be used to diagnose NAFLD, especially NASH. Here, KRT18 is linked to metabolic dysfunction-associated steatotic liver disease.